• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

January 23, 2025 by Deborah Bloomfield

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.

ADVERTISEMENT GO AD FREE

MDD is one of the most common mental health conditions in the US, affecting an estimated 21 million adults. Of those, around a third experience a treatment-resistant form of the condition; this means that their symptoms haven’t significantly alleviated after receiving standard treatments, such as at least two antidepressants and psychotherapy.

While there are existing avenues for such cases, including transcranial magnetic stimulation, researchers have also been exploring the possibility of using alternative antidepressant medications – that’s where the newly-approved nasal spray comes in.

Called SPRAVATO®, the nasal spray contains esketamine, a drug that is the chemical mirror-image (enantiomer) of the anesthetic drug ketamine. It had previously been FDA-approved back in 2019 – with some controversy, given the addictive nature of ketamine – for use with oral antidepressants.

Now, according to its manufacturer Johnson & Johnson, fresh clinical trial data has shown that the spray is effective on its own; at week 4 of the study, 22.5 percent of the patients taking SPRAVATO® had achieved remission from their treatment-resistant MDD, compared to 7.6 percent of the placebo group.

Like other antidepressants, the exact mechanism by which esketamine works to reduce depressive symptoms is unknown. However, esketamine increases levels of glutamate, an excitatory neurotransmitter.

Given the potential for abuse, there’s also some controversy over the use of esketamine as a treatment for depression. However, its approval doesn’t mean that it’ll be handed out with reckless abandon – the spray will only be available through a restricted program and can only be administered in a healthcare setting.

ADVERTISEMENT GO AD FREE

Patients will then have to be monitored by a healthcare provider for at least two hours for serious side effects – despite its apparent effectiveness, esketamine can still have side effects. According to Johns Hopkins Medicine, these can range from nausea and a headache all the way through to dissociation and hallucinations, though they tend to peak at around 40 minutes after the drug is administered and decrease thereafter.

Nonetheless, those behind the development of the spray are hopeful that its approval will make a difference to people with MDD.

“Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, healthcare providers have had few options to offer patients much-needed symptom improvement,” said Dr Bill Martin, Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine, in a statement.

Now, Martin continued, “patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral antidepressants.”

ADVERTISEMENT GO AD FREE

If you or someone you know is struggling, help and support are available in the US via the 988 Suicide & Crisis Lifeline which can be contacted by dialing 988. In the UK and Ireland, the Samaritans can be contacted on 116 123. International helplines can be found at SuicideStop.com.   

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. China develops machines that can track data sent abroad by cars
  2. Russia arrests top cybersecurity executive in treason case
  3. Is LK-99 A Superconductor Or Not? What To Know About Recent Superconductor Claims
  4. Incredibly Rare Footage Of Bigfin Squid 3,300 Meters Deep In The Pacific

Source Link: FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

Filed Under: News

Primary Sidebar

  • Did You Know The World’s Largest Waterfall Is Underwater?
  • Video Game Study Found Out What People Do When The World Ends, And It’s Exactly What You’d Expect
  • How Do We Predict The Weather? Find Out More In Issue 40 Of CURIOUS – Out Now
  • You Should Never Leave These Foods In Your Fridge Door (But We Bet You Do)
  • These Gullies On Mars Look Carved – We Might Finally Know What Created Them
  • Potential Environmental Trigger For Autism Identified, 3I/ATLAS’s Tail Appears To Have Changed Direction, And Much More This Week
  • Spaghetti Has Inner Secrets We’re Only Just Learning About
  • How Far Back In Time Could You Go And Still Understand English?
  • We Now Know How The First People Reached America – And It Wasn’t On Foot
  • Two Major Coral Species Now Functionally Extinct In Florida Keys, After Record-Breaking Marine Heatwave
  • A “Super-Earth” In The Habitable Zone Is Half The Distance To Comparable Worlds
  • Adorable But Critically Endangered Bornean Orangutan Born In Conservation Success
  • How Did The FDA Settle On The “2,000 Calories Per Day” Guideline?
  • Comet 3I/ATLAS Losing At Least Two Kangaroos’ Worth Of Dust Every Second
  • Mummified Dinosaur Duo Prove They Had Hooves, Marking “The First Confirmed Hooved Reptile”
  • What Do The Numbers On Your Toaster Really Mean?
  • NASA Vs. Elon Musk: Is A Moon Landing This Decade Off The Cards?
  • Scientists Explored Some Of The Deepest Parts Of The Ocean And Spotted Some Seriously Weird Deep-Sea Creatures
  • 500-Meter-Tall Megatsunami Struck Remote Alaskan Fjord After Massive Landslide
  • 3I/ATLAS, CKM Syndrome, And Mosquitoes’ Final Frontier
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version